Dear Editor,
Coronavirus disease 2019 (COVID-19) is associated with severe systemic inflammation and important elevation of fibrinogen and D-dimers that has been associated with a poor prognosis [1, 2]. This proinflammatory state might favor severe thromboembolic events and pulmonary embolism (PE).
Anzeige
We retrospectively reviewed characteristics of patients with confirmed SARS-CoV-2 infection and acute PE who were admitted to our tertiary ICU, which serves as an ECMO referral center for the Greater Paris. In accordance with the ethical standards of French legislation, only non-opposition of patient’s surrogate for utilization of the deidentified data was obtained. The ICU database was registered with the national data protection authority (CNIL 1950673). No analysis for statistical significance was performed given the descriptive nature of the study.
From February 25, 2020, to April 6, 2020, 51 patients with confirmed SARS-CoV-2 infection were treated in our ICU, of whom 8 (16%) had confirmed severe PE. Patients’ main characteristics are described in Table 1. Four patients had PE while on VV-ECMO for severe ARDS. VA-ECMO was initiated in 3 other patients with refractory shock due to right ventricular failure, and one patient died of refractory cardiac arrest before ECMO could be installed. PE was suspected in 6 patients because of acute cor pulmonale at echocardiographic evaluation (online supplementary data). PE diagnosis was confirmed by CT angiography (online supplementary data) in 7 patients and by autopsy in one patient. All except one had received anticoagulation before PE diagnosis. Five patients had a very high level of fibrinogen, and all had important increase in D-dimers. As of April 6, 2020, 3 patients had died of multiple organ failure and 5 are still on MV and ECMO in the ICU.
Table 1
Characteristics of the 8 COVID-19 patients who developed massive pulmonary embolism
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
|---|---|---|---|---|---|---|---|---|
Baseline characteristics | ||||||||
Age | 60 | 64 | 41 | 59 | 65 | 61 | 55 | 49 |
Gender | M | M | M | F | M | F | F | F |
BMI, kg/m2 | 32 | 27 | 31 | 39 | 32 | 27 | 33 | 30 |
Comorbidities | ||||||||
Hypertension | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
Diabetes | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Active smoker | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Heart disease | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Stroke | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical characteristics at the time of PE diagnosis | ||||||||
MV duration, days | 7 | 8 | 3 | 10 | 0 | 4 | 9 | 1 |
Reason for pulmonary embolism suspicion* | 1, 2, 3 | 1, 3 | 1, 2 | 1 | 4 | 2, 3 | 1, 2, 3 | 1 |
Norepinephrine, mg/h | 50 | 3 | 0 | 0 | 0 | 0.6 | 0 | 5 |
Acute kidney injury requiring dialysis | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
On VV-ECMO for severe ARDS | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
Anticoagulant therapy | Dalteparin, 5000 U/day | UFH, 12,000 U/day | Enoxaparin, 6000 U/day | UFH, 12,000 U/day | None | Enoxaparin, 6000 U/day | Enoxaparin, 8000 U/day | Enoxaparin, 8000 U/day |
Laboratory findings at the time of PE diagnosis | ||||||||
D-dimers, ng/mL | – | 7280 | 16,450 | > 20,000 | – | 15,360 | > 20,000 | > 20,000 |
Fibrinogen, g/dl | 8.7 | 7.8 | 9.8 | 3.6 | 3.2 | 8.2 | 6.3 | 2.5 |
aPTT ratio** | 1.05 | 1.18 | 1.27 | 1.14 | – | – | 1.23 | 1.2 |
Anti-Xa activity, U/mL | – | < 0.2 | – | < 0.2 | – | – | < 0.2 | < 0.2 |
Troponin, ng/L | < 13 | 28 | 131 | 59 | 13 | 16 | 42 | 168 |
White blood cell count, G/L | 13.8 | 16.1 | 16.5 | 23.4 | 6.1 | 11 | 17.5 | 12.8 |
Neutrophils, g/dl | 13 | 14.4 | 14.2 | 20.6 | 3.4 | 9.9 | 15.3 | 10.9 |
Lymphocytes, g/dl | 0.4 | 0.5 | 0.7 | 1.7 | 1.7 | 0.7 | 1.3 | 1.3 |
Hemoglobin, g/dl | 13 | 11.5 | 12.3 | 10.3 | 11.7 | 7.4 | 7 | 10.5 |
Platelet count, × 103/μL | 244 | 610 | 242 | 128 | 114 | 237 | 335 | 228 |
pH | 7.06 | 6.94 | 7.41 | 7.45 | 7.27 | 7.29 | 7.2 | 7.06 |
pCO2, mmHg | 63 | 59 | 41 | 40 | 43 | 70 | 79 | 36 |
pO2, mmHg | 40 | 75 | 54 | 66 | 84 | 60 | 60 | 177 |
PO2/FiO2 | 40 | 75 | 54 | 69 | NA | 66 | 60 | 177 |
Lactate, mmol/L | 28 | 9 | 2 | 1.7 | 1.4 | 0.9 | 1.7 | 8.5 |
ASAT, U/L | 37 | 43 | 108 | 71 | 53 | 63 | 62 | 2509 |
ALAT, U/L | 23 | 29 | 45 | 67 | 24 | 42 | 96 | 1207 |
LDH, U/L | – | 512 | 821 | 894 | 264 | 388 | 541 | 5884 |
Total bilirubin, mmol/L | 8 | 61 | 12 | 16 | 22 | 41 | 8 | 25 |
Creatinine kinase, IU/L | 34 | 103 | 3648 | 105 | 41 | 234 | 203 | 151 |
Outcomes | ||||||||
Received VA-ECMO for PE-associated shock | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Current status as of April 6, 2020 | Dead | Dead | In ICU, ongoing MV and ECMO | In ICU, ongoing MV and ECMO | Dead | In ICU, ongoing MV and ECMO | In ICU, ongoing MV and ECMO | In ICU, ongoing MV and ECMO |
We describe a series of 8 critically ill patients with massive PE following COVID-19 infection. Four of these patients developed PE while on VV-ECMO for severe ARDS, a condition that was not reported in the 156 patients included in the EOLIA trial [3] who received ECMO and in the 350 VV-ECMO patients of the LIFEGARDS international multicenter prospective cohort [4]. Interestingly, 7 of the 8 patients had received preventive anticoagulation that did not prevent PE. In 6 of the 8 patients, Doppler echocardiography showing acute right ventricle dilation prompted CT angiography that confirmed PE.
Massive PE in COVID-19 patients may be the consequence of sepsis-induced disseminated intravascular coagulation or to a specific procoagulant state caused by inflammation or virus-induced endothelial dysfunction [5]. Important elevation of D-dimers was indeed reported in these patients and was associated with subsequent ARDS and in-hospital mortality [5]. However, massive PE was not reported in previous series [1, 2], although it may have been the unproven cause of death in some patients.
Anzeige
Our observation has potential major clinical implications. First, higher level of anticoagulation might be considered in patients with the most severe forms of the disease, those with high D-dimers and, contrarily to our previous recommendation, in patients supported by VV-ECMO [3]. Second, routine Doppler echocardiography should be performed daily to detect early signs of acute cor pulmonale in critically ill patients. Lastly, PE should also be suspected in COVID-19 patients with worsening hypoxemia or hypercapnia under mechanical ventilation.
This case series has several limitations. It is a small single-center case series of critically ill patients, we did not compare clinical and biological characteristics of patients with or without PE, and PE incidence could not be accurately estimated. However, we think that physicians should be warned about the occurrence of severe and potentially fatal PE in COVID-19 patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13054-020-02931-5.
Acknowledgments
The authors thank Corinne Frère1 MD, PhD, and Pascal Leprince3 MD, PhD, for their help during the preparation of the manuscript.
Ethics approval and consent to participate
In accordance with French law and the ethical standards of our hospitals’ institutional review board (Committee for the Protection of Human Subjects), informed consent was not obtained because this observational study did not modify existing diagnostic or therapeutic strategies. However, patients and/or their relatives were informed about the anonymous data collection and were told that they could decline inclusion. This database is registered at the National Commission for Informatics and Liberties (CNIL registration no. 1950673).
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.